USMLE Step 3 Quiz
Practice Chronic Coronary Disease Management in USMLE Step 3 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
Question 1 / 20
0 of 20 answered
A 48-year-old woman presents with exertional chest pressure. A subsequent exercise stress test without imaging was terminated early due to chest pain and 2 mm of ST-segment depression in the lateral leads. Coronary angiography reveals non-obstructive coronary artery disease with 30-40% stenosis in several vessels. Her symptoms persist despite medical therapy with a beta-blocker and calcium channel blocker.
Which of the following is the most likely diagnosis?
This quiz focuses on Chronic Coronary Disease Management, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A 48-year-old woman presents with exertional chest pressure. A subsequent exercise stress test without imaging was terminated early due to chest pain and 2 mm of ST-segment depression in the lateral leads. Coronary angiography reveals non-obstructive coronary artery disease with 30-40% stenosis in several vessels. Her symptoms persist despite medical therapy with a beta-blocker and calcium channel blocker.
Which of the following is the most likely diagnosis?
Explanation: When you encounter a patient with chest pain and positive stress testing but non-obstructive coronary disease, think beyond the major epicardial vessels. This scenario points to dysfunction at the microvascular level. Coronary microvascular dysfunction (CMD) is the correct diagnosis here. This patient demonstrates the classic triad: anginal symptoms with exertional triggers, objective evidence of ischemia (positive stress test with ST depression), and angiographically normal or near-normal coronary arteries. The 30-40% stenoses are hemodynamically insignificant and cannot explain her symptoms. CMD affects the small resistance vessels (<500 micrometers) that regulate coronary flow but aren't visible on angiography. Women are disproportionately affected, and symptoms often persist despite standard anti-anginal therapy. Option A, Prinzmetal angina, involves coronary vasospasm but typically occurs at rest, not with exertion, and would show transient ST elevation rather than depression. Option B, esophageal spasm, wouldn't produce the characteristic lateral lead ST changes or positive exercise stress test findings. Option C, anxiety-related chest pain, is a diagnosis of exclusion that doesn't explain the objective ischemic changes on stress testing. The key study tip for USMLE Step 3: When you see exertional chest pain with positive stress testing but normal coronaries, especially in middle-aged women, strongly consider microvascular dysfunction. This represents an important cause of "chest pain with normal coronaries" and requires different management approaches than typical coronary artery disease.
Robert, 66, BMI 34 with stable CAD asks lifestyle advice; smokes, BP 142/86, LDL 118 on statin. What lifestyle modification would most benefit him?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the obese patient with stable CAD who smokes and has elevated BP and LDL requires prioritized lifestyle changes to reduce cardiovascular risk. The correct choice reflects smoking cessation and adopting a Mediterranean-style diet, which addresses major modifiable risks and aligns with evidence-based guidelines for secondary prevention. A common distractor might suggest avoiding all exercise until repeat angiography, which is unnecessary for stable disease and discourages beneficial physical activity. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
Nadia, 59, CAD, BMI 31, drinks sugary beverages daily; angina stable, LDL 76. What lifestyle modification would most benefit her?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the obese patient with stable CAD consumes sugary beverages, needing dietary tweaks for weight and metabolic control. The correct choice reflects replacing sugary drinks with water and reducing refined carbs, which aids weight loss and aligns with guidelines. A common distractor might suggest adopting a no-carb diet with unlimited processed meats, which increases saturated fat and cardiovascular risk. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
Marisol, 57, CAD, BMI 32, prediabetes, BP 138/84 on meds; walks 10 min daily. What lifestyle modification would most benefit her?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the patient with CAD, obesity, prediabetes, and limited activity needs to enhance exercise for risk reduction. The correct choice reflects increasing moderate aerobic activity to 150 minutes per week, which improves cardiovascular health and aligns with guidelines. A common distractor might suggest avoiding exercise, which is detrimental and contradicts recommendations for physical activity in stable CAD. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
A 68-year-old man with a history of a drug-eluting stent placed in the left anterior descending artery two years ago for stable angina presents for a follow-up visit. He is currently on aspirin 81 mg, atorvastatin 80 mg, lisinopril 20 mg, and metoprolol succinate 100 mg daily. He reports that for the past three months, his anginal symptoms, which were previously well-controlled, now occur with less exertion, about 3-4 times per week. His vital signs are stable, and physical examination is unremarkable. An ECG shows normal sinus rhythm with no new ischemic changes. His most recent LDL cholesterol was 65 mg/dL.
In addition to sublingual nitroglycerin for acute symptoms, which of the following is the most appropriate next step in managing this patient's condition?
Explanation: This patient has stable coronary artery disease and is experiencing an increase in anginal symptoms despite being on guideline-directed medical therapy (GDMT). The first-line treatment for angina is beta-blockers. Before adding a second agent or proceeding to invasive testing, the initial therapy should be optimized. The maximum recommended dose for metoprolol succinate is 400 mg daily, so his current dose of 100 mg can be safely increased. Titrating the beta-blocker to the maximally tolerated dose to control heart rate and symptoms is the most appropriate next step.
A 72-year-old woman with a history of coronary artery disease (CAD), hypertension, and type 2 diabetes mellitus presents for routine follow-up. Her CAD was managed with a percutaneous coronary intervention (PCI) with a drug-eluting stent to the right coronary artery 18 months ago. She is asymptomatic from a cardiac standpoint. Her medications include aspirin, clopidogrel, rosuvastatin, metformin, and lisinopril. Today, she is diagnosed with new-onset nonvalvular atrial fibrillation. Her heart rate is 88/min and blood pressure is 134/82 mm Hg. Her CHA₂DS₂-VASc score is calculated to be 6.
Which of the following is the most appropriate long-term management plan for this patient's antithrombotic therapy?
Explanation: This patient requires anticoagulation for atrial fibrillation (CHA₂DS₂-VASc score of 6) and is >12 months post-PCI with drug-eluting stent. Current guidelines recommend dual therapy with oral anticoagulation plus single antiplatelet therapy rather than triple therapy to reduce bleeding risk while maintaining ischemic protection. Aspirin is preferred over clopidogrel for the single antiplatelet agent in this setting. Triple therapy (option A) significantly increases bleeding risk and is not recommended for long-term use. Anticoagulation monotherapy (option C) may be considered but combination therapy is more commonly recommended. Option D uses a less optimal antiplatelet choice.
A 59-year-old woman with known coronary artery disease, status post-CABG seven years ago, is seen for an annual wellness visit. She is completely asymptomatic, walks 3 miles daily without chest pain or dyspnea, and has well-controlled hypertension and hyperlipidemia. Her medications are aspirin, atorvastatin, and amlodipine. Her physical examination and ECG are unchanged from last year.
Which of the following is the most appropriate recommendation regarding cardiac surveillance?
Explanation: Current guidelines do not recommend routine surveillance stress testing or anatomic imaging for asymptomatic patients with known stable CAD, including those post-revascularization (PCI or CABG). Such testing is not shown to improve outcomes and can lead to unnecessary downstream procedures and costs. Testing is reserved for patients who develop new or worsening symptoms. Since this patient is asymptomatic with a good functional capacity and her risk factors are well-managed, the most appropriate approach is to continue optimal medical therapy and clinical follow-up without further cardiac imaging.
A 67-year-old man with stable angina, type 2 diabetes, and hypertension is treated with aspirin, metoprolol, lisinopril, and metformin. His LDL cholesterol is 95 mg/dL. He was started on atorvastatin 40 mg daily one month ago but stopped it after two weeks due to severe bilateral thigh pain and weakness that resolved upon discontinuation. He is unwilling to try another statin.
Which of the following is the most appropriate next step in managing his dyslipidemia?
Explanation: This patient has statin intolerance and an LDL level above the goal of <70 mg/dL (and often <55 mg/dL in very high-risk patients like this one). While trying a different statin at a low dose (C) is a reasonable strategy for statin-associated muscle symptoms, the patient is currently unwilling to do so. Therefore, the next best step is to add a non-statin agent. Ezetimibe is the first-line non-statin agent recommended by guidelines to lower LDL cholesterol. Fenofibrate (B) primarily targets triglycerides and has limited LDL-lowering effects and no proven mortality benefit in this setting. Niacin (D) is no longer recommended for routine use due to side effects and lack of proven benefit on cardiovascular outcomes when added to a statin.
A 62-year-old man with a history of stable CAD presents with worsening exertional angina over the past month. He is now limited to walking one block. His current medications include aspirin 81 mg, metoprolol succinate 200 mg daily, atorvastatin 80 mg daily, and isosorbide mononitrate 60 mg daily. His blood pressure is 110/70 mm Hg and heart rate is 55/min. He uses sublingual nitroglycerin two to three times per day.
Which of the following is the most appropriate next step in this patient's management?
Explanation: This patient has lifestyle-limiting angina despite being on maximal or near-maximal doses of two antianginal agents (beta-blocker and long-acting nitrate). His heart rate and blood pressure are at the lower limits of normal, limiting further dose titration of beta-blockers or nitrates, and making the addition of a calcium channel blocker (amlodipine) problematic due to potential hypotension. While adding ranolazine (B) is an option for medical therapy, the severity of his symptoms despite an aggressive medical regimen makes him a candidate for revascularization. Therefore, the most appropriate next step is to proceed with coronary angiography to define his coronary anatomy and assess options for percutaneous coronary intervention or coronary artery bypass grafting.
A 58-year-old man had a drug-eluting stent placed in his circumflex artery three weeks ago for an NSTEMI. He was discharged on aspirin, ticagrelor, atorvastatin, and metoprolol. He now requires urgent cholecystectomy for acute cholecystitis. He is hemodynamically stable.
Which of the following is the most appropriate management of his antiplatelet therapy in the perioperative period?
Explanation: This patient requires urgent surgery less than one month after receiving a drug-eluting stent (DES), placing him at very high risk for stent thrombosis if antiplatelet therapy is interrupted. The ideal scenario is to postpone elective surgery for at least 6 months. However, this surgery is urgent. The current consensus for managing dual antiplatelet therapy (DAPT) in this high-risk situation is to continue aspirin throughout the perioperative period to provide some protection against stent thrombosis, while holding the P2Y12 inhibitor (ticagrelor) for a short period (3-5 days) to reduce surgical bleeding risk. Continuing both (A) poses a very high bleeding risk. Holding both (B) poses an unacceptably high risk of stent thrombosis. Bridging therapy (D) is complex, expensive, and its efficacy in this setting is not well established; holding aspirin is also incorrect.
A 75-year-old woman with chronic stable angina and chronic kidney disease (eGFR 25 mL/min/1.73 m²) presents for medication review. She reports occasional chest tightness with exertion, relieved by rest. Her medications include aspirin, clopidogrel, atorvastatin, and metoprolol. Her heart rate is 65/min and blood pressure is 145/88 mm Hg. She has 1+ pedal edema.
Her physician wants to add another agent for better blood pressure and angina control. Which of the following is the most appropriate choice?
Explanation: This patient needs additional therapy for both hypertension and angina. Amlodipine, a dihydropyridine calcium channel blocker, is an effective antihypertensive and antianginal agent. It is safe in chronic kidney disease and would be a good choice. Lisinopril (A) is an excellent antihypertensive and is indicated in CKD, but it has minimal antianginal effects. Ranolazine (C) is an antianginal but has little effect on blood pressure and requires dose adjustment in severe CKD. Hydrochlorothiazide (D) is ineffective as an antihypertensive when eGFR is <30 mL/min/1.73 m² and has no antianginal properties. Amlodipine addresses both of the patient's clinical needs appropriately.
A 69-year-old man with known three-vessel coronary artery disease, deemed not a candidate for revascularization, has persistent class III angina despite maximal medical therapy. His regimen includes high-dose metoprolol, isosorbide mononitrate, and amlodipine. His blood pressure is 105/60 mm Hg and heart rate is 58/min. He is frustrated with his limited quality of life.
Which of the following interventions is most likely to improve this patient's symptoms?
Explanation: This patient has refractory angina, defined as persistent symptoms despite optimal medical and revascularization therapies. He is already on three agents, and his hemodynamics limit further titration or additions of traditional drugs (e.g., ranolazine is an option, but another may be better). Enhanced external counterpulsation (EECP) is a non-invasive therapy indicated for patients with refractory angina who are not candidates for revascularization. It has been shown to improve anginal symptoms and quality of life. Adding another nitrate (C) is unlikely to help given he is on a long-acting one and is borderline hypotensive. Cardiac rehabilitation (D) is beneficial but may be difficult for a patient with class III angina to participate in fully; EECP directly targets the pathophysiology of his refractory symptoms.
A 71-year-old man with chronic CAD is admitted with a non-ST-elevation myocardial infarction (NSTEMI). He undergoes successful PCI with a drug-eluting stent to the obtuse marginal artery. His ejection fraction is preserved at 55%. His home medications included aspirin and atorvastatin. At discharge, he is prescribed aspirin, clopidogrel, atorvastatin, and lisinopril.
Which of the following additional medications should be prescribed for long-term secondary prevention?
Explanation: Beta-blockers are a cornerstone of post-MI care. They have been shown to reduce mortality, reinfarction, and sudden cardiac death. They should be initiated in all patients post-MI unless contraindicated. The benefit is most established in patients with reduced ejection fraction, but they are still recommended for at least three years in patients with preserved EF. Aldosterone antagonists like spironolactone (A) and eplerenone (D) are indicated post-MI only in patients with an LVEF ≤40% and either heart failure symptoms or diabetes. Long-acting nitrates (C) are used for symptom control of angina and do not provide a mortality benefit.
A 63-year-old woman with known CAD, peripheral artery disease (PAD), and asthma presents for follow-up. She continues to have exertional angina despite taking aspirin, atorvastatin, and amlodipine 10 mg daily. Her blood pressure is 130/80 mm Hg and heart rate is 85/min. Her asthma is well-controlled with an inhaled corticosteroid/long-acting beta-agonist.
Which of the following medications is the most appropriate addition to her regimen?
Explanation: This patient requires an additional antianginal agent. While beta-blockers are first-line, her history of asthma makes them relatively contraindicated, especially non-selective agents like propranolol (B). Even cardioselective beta-blockers like metoprolol (A) can potentially cause bronchospasm and should be used with caution. Nitrates (D) are an option, but ranolazine (C) is an excellent choice here. It reduces anginal frequency without affecting heart rate or blood pressure, making it a safe option in this patient who has a normal heart rate and blood pressure. It also has no adverse effects on bronchospasm or PAD symptoms.
A 60-year-old man post-MI is enrolled in a cardiac rehabilitation program. He is on aspirin, ticagrelor, rosuvastatin, and lisinopril. His ejection fraction is 35%. During a supervised exercise session, he develops non-sustained ventricular tachycardia (NSVT) on telemetry but remains asymptomatic. He has no angina, and his vital signs are stable.
Which of the following is the most appropriate immediate action?
Explanation: This patient has a reduced ejection fraction post-MI and is not on a beta-blocker, which is a key component of guideline-directed medical therapy for mortality reduction and arrhythmia prevention. Asymptomatic NSVT in this setting is common and, while it is a marker of increased risk, the first step is to ensure the patient is on optimal medical therapy. Initiating a beta-blocker (e.g., carvedilol, metoprolol succinate) is the most appropriate next step. Discontinuing rehab (A) is premature. Immediate admission for an EP study (C) is not warranted for asymptomatic NSVT without optimizing medical therapy first. Amiodarone (D) is reserved for symptomatic or sustained arrhythmias and does not have a mortality benefit for primary prevention in this setting.
A 64-year-old woman with a history of MI and an LVEF of 40% has stable NYHA class II heart failure symptoms. Her regimen includes lisinopril 20 mg, carvedilol 25 mg twice daily, spironolactone 25 mg, and atorvastatin 80 mg. Her blood pressure is 115/70 mm Hg, heart rate is 68/min, and potassium is 4.2 mEq/L. She has type 2 diabetes managed with metformin.
Which of the following medication classes, when added to her current regimen, has been shown to provide additional mortality benefit in this patient population?
Explanation: Heart failure with reduced ejection fraction (HFrEF) management follows evidence-based guidelines that prioritize medications with proven mortality benefits. This patient has optimal guideline-directed medical therapy with an ACE inhibitor, beta-blocker, and mineralocorticoid receptor antagonist, plus she has diabetes—a key detail for considering newer therapeutic options. SGLT2 inhibitors represent a breakthrough in HFrEF treatment. Large randomized trials (DAPA-HF, EMPEROR-Reduced) demonstrated that drugs like dapagliflozin and empagliflozin reduce cardiovascular death and heart failure hospitalizations in patients with HFrEF, regardless of diabetes status. The mechanism involves improved cardiac metabolism, reduced preload, and potential direct cardioprotective effects beyond glucose lowering. Option A (ARB) would typically only be considered if the patient couldn't tolerate an ACE inhibitor, as adding both provides no additional mortality benefit and increases hyperkalemia risk. Option B (digoxin) can improve symptoms and reduce hospitalizations but doesn't reduce mortality—the RADIANCE and DIG trials showed no survival benefit. Option C (loop diuretic) treats volume overload symptoms but has no mortality benefit; this patient shows no signs of fluid retention requiring diuretic therapy. For USMLE Step 3, remember that heart failure questions increasingly test knowledge of newer evidence-based therapies. When you see a diabetic patient with optimized HFrEF therapy, think SGLT2 inhibitors—they're now Class I recommendations in heart failure guidelines. Focus on which medications actually improve survival, not just symptoms.
A 66-year-old woman with a history of MI two years ago is on optimal medical therapy including high-intensity statin. Her baseline LDL was 150 mg/dL. On atorvastatin 80 mg, her LDL is 75 mg/dL. She has no side effects from her medication. She also has well-controlled type 2 diabetes. She asks if her cholesterol is low enough.
Which of the following is the most appropriate next step in the management of her hyperlipidemia?
Explanation: This patient has atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes, placing her in the very high-risk category. For such patients, the LDL cholesterol goal is <70 mg/dL, and some guidelines suggest a goal of <55 mg/dL. Her LDL is 75 mg/dL on a maximally tolerated high-intensity statin. Therefore, her LDL is not at goal (A). The next step according to guidelines is to add a non-statin agent. Ezetimibe is the recommended first-choice add-on therapy. Switching to an equivalent or more potent statin (C) is unlikely to provide significant additional LDL reduction as she is already on a high-intensity dose. Fenofibrate (D) is not indicated for LDL lowering and has not been shown to reduce cardiovascular events when added to a statin in this population.
Paul, 73, 2 weeks post-PCI, on aspirin+clopidogrel, reports black stools and dizziness; BP 96/60. Based on symptoms, what is next best step?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the patient early post-PCI on DAPT presents with black stools and hypotension, suggesting possible GI bleeding. The correct choice reflects urgent evaluation for GI bleeding while coordinating antiplatelet management, aligning with guidelines for balancing bleeding and thrombotic risks. A common distractor might suggest reassuring and continuing without evaluation, which risks missing serious hemorrhage. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
Olga, 68, stable CAD, HTN, smoker, wants diet advice; LDL 92 on statin, A1c 6.1. What lifestyle modification would most benefit her?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the smoking patient with stable CAD, HTN, and prediabetes seeks diet advice, highlighting the need to prioritize high-impact changes. The correct choice reflects smoking cessation with pharmacotherapy and counseling, as it offers the greatest risk reduction and aligns with guidelines. A common distractor might suggest avoiding fruits and vegetables, which contradicts heart-healthy diet recommendations and limits nutritional benefits. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.
Elena, 64, stable CAD, overweight, sedentary, LDL 80 on statin; angina only climbing 2 flights. What lifestyle modification would most benefit her?
Explanation: This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the overweight, sedentary patient with stable CAD and exertional angina needs lifestyle interventions to improve symptoms and risk profile. The correct choice reflects a structured cardiac rehab aerobic exercise program, which enhances functional capacity and aligns with guidelines for secondary prevention. A common distractor might suggest avoiding walking to prevent ischemia, which is counterproductive and limits beneficial activity in stable disease. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.